10-Q: NextPlat Narrows Q3 Loss Amid Revenue Decline, Cost Cuts

NextPlat Corp reported a significantly reduced net loss for the nine months ended September 30, 2025, driven by substantial operating expense reductions, despite an overall decrease in revenue.

Summary

• Net loss attributable to NextPlat Corp decreased by 52% to $5.3 million for the nine months ended September 30, 2025, compared to $11.0 million in the prior year period.
• Total revenue decreased by 17% to $41.5 million for the nine months ended September 30, 2025, down from $49.9 million in the same period of 2024.
• Gross profit declined by 36% to $9.1 million, with gross profit margins falling to 21.9% from 28.6% year-over-year.
• Operating expenses saw a substantial 59% reduction, totaling $14.4 million for the nine months ended September 30, 2025, compared to $35.0 million in the prior year.
• The decrease in operating expenses was primarily due to the absence of a $13.7 million impairment loss recognized in 2024, as well as reductions in salaries, wages, payroll taxes, and professional fees.
• e-Commerce revenue increased by 6% to $10.8 million, driven by growth in recurring airtime revenue and hardware sales.
• Healthcare Operations revenue decreased by approximately $9.0 million, primarily due to a $5.8 million drop in Pharmacy 340B contract revenue and a $3.2 million decrease in pharmacy prescription and other revenue.
• The decline in pharmacy prescription volume was influenced by changes in provider relationships and shifts in patient flow.
• A material weakness in inventory valuation controls, identified in fiscal 2024, was remediated by September 30, 2025, through new policies, senior management oversight, and enhanced data accuracy.
• The company settled an arbitration proceeding with a former employee of Progressive Care for $150,000 cash and $100,000 in NextPlat common stock, plus a consulting agreement with reverse stock-split protection.
• Warrants issued in December 2022 had their exercise period extended by 24 months, now expiring on December 14, 2027, in exchange for a release of claims from holders.
• A lease termination agreement for office space in Coconut Grove, FL, will result in an early termination fee of approximately $120,000.

Sentiment

Score: 5

Explanation: The company shows mixed results with significant improvements in net loss due to cost cutting and absence of impairment, but also notable revenue and gross profit declines in its core healthcare segment. The extension of warrants and ongoing litigation add elements of uncertainty, while the remediation of internal control weaknesses is a positive step. The overall sentiment is neutral to slightly positive, reflecting a company in transition, managing costs effectively but facing revenue challenges.

Positives

• Net loss attributable to NextPlat Corp significantly decreased by 52% to $5.3 million for the nine months ended September 30, 2025, compared to $11.0 million in the prior year, indicating improved loss management.
• Operating expenses were substantially reduced by 59% to $14.4 million, primarily due to the absence of a $13.7 million impairment loss and lower personnel and professional fees.
• e-Commerce revenue grew by 6% to $10.8 million, driven by increased recurring airtime revenue and hardware sales.
• A material weakness in inventory valuation controls was successfully remediated by implementing formalized policies, senior management oversight, and improved data accuracy.
• The company's existing cash resources of $13.9 million are deemed sufficient to support planned operations for the next 12 months.

Negatives

• Overall revenue decreased by 17% to $41.5 million for the nine months ended September 30, 2025, compared to $49.9 million in the prior year.
• Gross profit declined by 36% to $9.1 million, with gross profit margins decreasing from 28.6% to 21.9% year-over-year.
• Healthcare Operations revenue decreased by approximately $9.0 million, primarily due to a 66% drop in Pharmacy 340B contract revenue and a 10% decrease in pharmacy prescription and other revenue.
• Pharmacy prescription volume declined significantly, with approximately 294,000 prescriptions filled in the current nine-month period versus 395,000 in the prior year.
• The company incurred a $250,000 loss on settlement of litigation related to a former employee's arbitration proceeding, requiring cash and stock payments.
• An early termination fee of approximately $120,000 will be paid for the Coconut Grove, FL office lease termination.

Risks

• The current U.S./China tariff environment could adversely impact the company's e-Commerce business, financial prospects, and profitability, particularly for imported goods and future projects like the Florida Sunshine brand.
• Retaliatory tariffs by China create uncertainty, complicating sales forecasting, inventory management, and production planning for the Chinese market.
• Chinese authorities have broad discretion to change tariff rates or target specific U.S. companies, posing ongoing trade-policy risk.
• The pending class action lawsuit filed by Alan Jay Weisberg, alleging breach of fiduciary duty related to the RXMD merger, could result in significant compensatory and rescissory damages.
• The company faces general risks and difficulties frequently encountered by early-stage companies, particularly those in new and rapidly evolving markets and technologies, with a limited operating history.

Future Outlook

Management is exploring various strategic alternatives to diversify business operations, including opportunities in additional services, joint ventures, and other collaborative structures. The company expects its state-of-the-art e-Commerce platform, designed to help businesses optimize online sales, to become a future focus of the e-Commerce segment. The ongoing trade tensions between the U.S. and China may impact the success of future projects planned in China under the Florida E-Commerce Development Program, such as the launch of the Florida Sunshine range of vitamins.

Management Comments

• Management believes that the existing financial resources are sufficient to continue operating activities for at least one year past the issuance date of the consolidated financial statements.
• Management does not believe that the Weisberg claim is meritorious and plans to vigorously defend against the suit.

Industry Context

The company's Healthcare Operations segment experienced a significant decline in 340B contract revenue and prescription volume, indicating a challenging environment possibly due to competitive pressures, changes in provider relationships, and shifts in patient flow. This suggests a need for the company to adapt its strategy within the healthcare sector, potentially by focusing on higher patient engagement and clinical expertise as mentioned. The e-Commerce segment, while showing modest growth, faces headwinds from U.S. and Chinese tariffs, which could impact global expansion plans and product launches, reflecting broader geopolitical and trade challenges affecting international e-commerce.

Comparison to Industry Standards

• NA

Management Changes

Corporate Governance

Legal Proceedings

• A lawsuit filed on March 17, 2025, by a former employee of Pharmco LLC asserting claims under EEOC regulations was settled on October 14, 2025. The settlement was fully covered by the company's insurance policy.
• A putative class action suit filed on October 28, 2024, by Alan Jay Weisberg against NextPlat and directors, alleging breach of fiduciary duty in connection with the RXMD merger. The complaint seeks compensatory and rescissory damages in an unspecified amount. Management believes the claim is not meritorious and is vigorously defending against it, having filed a motion to dismiss.
• An arbitration proceeding initiated by Progressive Care against a former employee for alleged breach of employment contract was settled on November 7, 2025. The settlement includes a $150,000 cash payment, $100,000 in NextPlat common stock, a consulting agreement, and a one-time reverse stock-split protection mechanism for the stock.

Related Party Transactions

• Amounts due to David Phipps, CEO, for American Express accounts for Orbital Satcom Corp and GTC, totaled approximately $4,000 as of September 30, 2025, down from $18,000 as of December 31, 2024. These payables are non-interest bearing and due on demand.
• Wages were paid to one employee related to David Phipps (CEO) and one employee related to Amanda Ferrio (CFO) during the nine months ended September 30, 2025.
• Wages were paid to Lauren Sturges Fernandez, spouse of the late CEO Charles M. Fernandez, as Chief of Staff and Special Assistant to the Chairman of the Board, until her employment termination on August 13, 2025.

Stakeholder Impact

• Shareholders: The extension of warrant exercise periods provides more time for warrant holders to potentially benefit from stock appreciation, while the share repurchase program could support stock value. However, the issuance of $100,000 in stock for a legal settlement could cause minor dilution. The ongoing class action lawsuit poses a significant financial risk.
• Employees: The termination of Lauren Sturges Fernandez's employment indicates management restructuring. The settlement with a former employee resolves a dispute but involves a payout.
• Customers: Temporary rate reductions for some e-Commerce customers affected by service interruptions indicate efforts to maintain customer satisfaction. Changes in provider relationships and patient flow impacted healthcare customer base.
• Creditors: Repayments of notes payable and finance lease liabilities demonstrate ongoing debt management. The company's cash position is deemed sufficient for the next 12 months, which is positive for short-term creditors.

Next Steps

• File a Joint Stipulation of Dismissal of the Arbitration with Prejudice within three days of the Settlement Agreement execution.
• Enter into a Consulting Agreement with the former employee simultaneously with the Settlement Agreement execution.
• Issue additional shares to the former employee if the aggregate value of transferred shares declines by more than 20% within 60 days following a reverse stock split, within ten days after the 60-day period.
• Continue to implement cost reduction measures aimed at improving operational efficiency and preserving liquidity.
• Explore various strategic alternatives to diversify business operations, including opportunities in additional services, joint ventures, and other collaborative structures.
• Continue to vigorously defend against the Alan Jay Weisberg class action lawsuit and pursue the motion to dismiss the complaint.
• Review opportunities to sell Florida Sunshine products in other markets due to U.S. and Chinese tariffs.

Key Dates

Recommendation

NextPlat Corp presents a mixed financial picture. While the significant reduction in net loss and operating expenses, particularly the absence of large impairment charges, is a positive development, the underlying revenue decline in the core Healthcare Operations segment and falling gross profit margins are concerning. The e-Commerce segment shows some growth, but faces tariff-related headwinds. The extension of warrants provides flexibility but also signals a potential need to conserve cash or a lack of immediate upside for warrant holders to exercise. The ongoing class action lawsuit represents a material contingent liability. The remediation of internal control weaknesses is a good step for governance. Given the combination of improved loss management through cost controls and persistent revenue challenges, coupled with legal uncertainties, a 'hold' recommendation is appropriate. Investors should monitor the company's ability to stabilize and grow revenue, especially in its healthcare segment, and the outcome of the Weisberg litigation.

Keywords

e-Commerce, Healthcare Operations, Pharmacy, 340B contract revenue, Satellite communication services, SEC filing, Quarterly report, Financial results, Net loss, Operating expenses, Tariffs, Litigation, Warrants, Share repurchase, Internal controls, NASDAQ: NXPL